Cytosorbents Corporation
CTSOCytosorbents Corporation in brief
Cytosorbents Corporation is a listed company in the Medical Devices industry, based in Princeton, New Jersey, USA. It was founded in 1997. Its market value was $25 M on 1 August 2026, which makes it the 23,615th largest listed company in the world and the 4,088th largest in the USA on this site. In the year to December 2025 it had sales of $37 M and a net loss of $8 M. Phillip P. Chan is its chief executive. Its largest business segments by sales in 2025 were Single reportable segment (100%). Its shares trade under the symbol CTSO (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Cytosorbents Corporation
CytoSorbents Corporation is a publicly traded company located in Princeton, New Jersey.
CytoSorbents sells a cytokine adsorbing column ("CytoSorb" which received CE mark approval in 2011) — a blood purification technology based on porous polymer beads that act like sponges in an attempt to remove harmful inflammatory mediators like Cytokines, Bilirubin, Myoglobin from the blood.
The use of hemoperfusion columns is generally limited to patients who are critically ill in high-resource counties, and they require a patient to be connected to a hemofiltration system such as Dialysis, Hemofiltration Cardiopulmonary bypass or ECMO. Other blood purification devices are using different technologies with different performance parameters. This is including polymyxin B hemoperfusion columns (Toraymyxin), which failed to show significance in a clinical trial for sepsis. The CytoSorb technology has actually the largest body of clinical data confirming safety and efficacy. Clinicaltrials.gov is giving an overview over running research projects.
From Wikipedia: read the full article · text available under CC BY-SA 4.0
Cytosorbents Corporation timeline
- 1997
- 🏁· approximateFounded
- 2004
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2006
- ✎Renamed MedaSorb Technologies CORPFormerly Gilder Enterprises Inc.
- 2010
- ✎Renamed Cytosorbents CorpFormerly MedaSorb Technologies CORP.
- 2021
- 💰Record revenue of $43 millionFY2021, the highest of the 8 years on record.
Events of Cytosorbents Corporation from the company record, SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #3,578 (Jan 2020) · #2,846 (Jan 2021) · #4,018 (Jan 2022) · #4,643 (Dec 2022) · #3,773 (Jul 2023) · #4,038 (Jan 2024) · #2,140 (Mar 2026) · #3,905 (Aug 2026)
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- 0.7×
- Price / book
- 4.2×
- Free cash flow yield
- -50.2%
- Net margin (TTM)
- -49.0%
- Operating margin
- -39.8%
- Return on equity
- -308.8%
- Liabilities / assets
- 86.6%
- Net debt
- $10M
- Revenue growth
- +4.1%
- R&D / revenue
- 50.6%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $37M | +4.1% | $-15M | $-8M | -22.1% |
| Dec 2024 | $36M | +14.5% | $-16M | $-21M | -58.2% |
| Dec 2023 | $31M | -10.4% | $-32M | $-29M | -94.1% |
| Dec 2022 | $35M | -19.6% | $-32M | $-33M | -94.6% |
| Dec 2021 | $43M | +5.3% | $-23M | $-25M | -56.9% |
| Dec 2020 | $41M | +64.3% | $-10M | $-8M | -19.1% |
| Dec 2019 | $25M | +10.9% | $-19M | $-19M | -77.2% |
| Dec 2018 | $23M | — | $-16M | $-17M | -76.5% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-12M | $0M | $-13M | $-0.13 | — |
| Dec 2024 | $-14M | $0M | $-15M | $-0.38 | — |
| Dec 2023 | $-22M | $1M | $-22M | $-0.65 | — |
| Dec 2022 | $-28M | $6M | $-34M | $-0.75 | — |
| Dec 2021 | $-14M | $4M | $-18M | $-0.57 | — |
| Dec 2020 | $-6M | $1M | $-6M | $-0.20 | — |
| Dec 2019 | $-17M | $1M | $-17M | $-0.60 | — |
| Dec 2018 | $-11M | $1M | $-12M | $-0.56 | — |
Quarterly results
Latest quarter to Jun 2026: revenue $10M (+0.1% on a year earlier), net income $-4M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.
SEC filings
- Nov 12, 20268-KCurrent reportResults of operations
- Sep 23, 20268-KCurrent reportRegulation FD disclosure · Other events
- Sep 8, 20268-KCurrent reportBylaws amended
- Aug 14, 20268-KCurrent reportShareholder vote
- Aug 7, 20268-KCurrent reportRegulation FD disclosure
- Aug 6, 20268-KCurrent reportResults of operations
- Aug 6, 202610-QQuarterly report · period to Jun 2026
- Jul 6, 20268-KCurrent reportListing notice
- Jun 25, 2026DEF 14AProxy statement
- Jun 25, 20268-KCurrent reportRegulation FD disclosure
- May 13, 202610-QQuarterly report · period to Mar 2026
- May 13, 20268-KCurrent reportResults of operations
Official filings of Cytosorbents Corporation with the US Securities and Exchange Commission.
Annual results
- Revenue
- $37 M
- Operating income
- $-15 M
- Net income
- $-8 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $44 M
- Total liabilities
- $38 M
- Total equity
- $6 M
As of December-2025
Top 26 institutional investors in Cytosorbents Corporation#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Vanguard Capital Management LLC | 94,223 | New | 0.15% | $0 M | Nov 13, 2026 |
| 2 | CM Management, LLC | 73,825 | New | 0.12% | $0 M | Nov 12, 2026 |
| 3 | Neuberger Berman Group LLC | 58,187 | New | 0.09% | $0 M | Nov 13, 2026 |
| 4 | Skylands Capital, LLC | 39,526 | New | 0.06% | $0 M | Oct 21, 2026 |
| 5 | BlackRock, Inc. | 31,360 | New | 0.05% | $0 M | Nov 13, 2026 |
| 6 | Geode Capital Management, LLC | 30,099 | New | 0.05% | $0 M | Nov 6, 2026 |
| 7 | Pathstone Holdings, LLC | 27,491 | New | 0.04% | $0 M | Nov 13, 2026 |
| 8 | Sargent Investment Group, LLC | 25,788 | New | 0.04% | $0 M | Nov 13, 2026 |
| 9 | Vanguard Fiduciary Trust Co | 15,806 | New | 0.03% | $0 M | Nov 13, 2026 |
| 10 | UBS Group AG | 8,302 | New | 0.01% | $0 M | Nov 10, 2026 |
| 11 | Osaic Holdings, Inc. | 6,420 | New | 0.01% | $0 M | Nov 12, 2026 |
| 12 | Morgan Stanley | 4,202 | New | 0.01% | $0 M | Nov 13, 2026 |
| 13 | Tower Research Capital LLC (TRC) | 1,486 | New | 0.00% | $0 M | Nov 16, 2026 |
| 14 | Nuveen, LLC | 1,462 | New | 0.00% | $0 M | Nov 10, 2026 |
| 15 | Vanguard Global Advisers, LLC | 694 | New | 0.00% | $0 M | Nov 13, 2026 |
| 16 | Wells Fargo & Company/mn | 612 | New | 0.00% | $0 M | Nov 16, 2026 |
| 17 | Northwestern Mutual Wealth Management Co | 558 | New | 0.00% | $0 M | Nov 13, 2026 |
| 18 | Rockefeller Capital Management L.P. | 82 | New | 0.00% | $0 M | Nov 13, 2026 |
| 19 | Global Retirement Partners, LLC | 52 | New | 0.00% | $0 M | Nov 10, 2026 |
| 20 | Fifth Third Bancorp | 26 | New | 0.00% | $0 M | Nov 5, 2026 |
| 21 | Jpmorgan Chase & Co | 19 | New | 0.00% | $0 M | Nov 12, 2026 |
| 22 | Farther Finance Advisors, LLC | 9 | New | 0.00% | $0 M | Oct 8, 2026 |
| 23 | Russell Investments Group, Ltd. | 2 | New | 0.00% | $0 M | Nov 6, 2026 |
| 24 | PNC Financial Services Group, Inc. | 1 | New | 0.00% | $0 M | Nov 6, 2026 |
| 25 | Danske Bank A/s | 1 | New | 0.00% | $0 M | Nov 9, 2026 |
Show all 26: investors 26 to 26
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | BNP Paribas Financial Markets | 1 | New | 0.00% | $0 M | Nov 12, 2026 |
Mutual funds holding Cytosorbents Corporation#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 1.27 M | $0 M | 2.0% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Neuberger Intrinsic Value FundNeuberger Berman Investment Advisers LLC | 646,511 | $0 M | 1.0% | 0.02% | −0.1% | May 31, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 574,463 | $0 M | 0.91% | <0.01% | +6.3% | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 380,268 | $0 M | 0.61% | <0.01% | +28% | May 31, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 94,319 | $0 M | 0.15% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 78,580 | $0 M | 0.13% | <0.01% | +5.0% | May 31, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 32,102 | $0 M | 0.05% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 35,641 | $0 M | 0.06% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc. | 29,596 | $0 M | 0.05% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Morgan Stanley Pathway Small-Mid Cap Equity ETFCONSULTING GROUP ADVISORY SERVICES LLC | 21,766 | $0 M | 0.03% | <0.01% | −4.9% | May 31, 2026 |
| 🇺🇸 Column Small Cap Select FundTrust for Professional Managers | 6,741 | $0 M | 0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Column Small Cap FundTrust for Professional Managers | 2,079 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 12 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Cytosorbents Corporation#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Phillip P. ChanChief Executive Officer, Director | Buy | +3,774 | $6.000 | $23 K | 100,996 | Form 4 |
| filed | Alan D. SobelDirector | Buy | +1,900 | $6.120 | $12 K | 9,287 | Form 4 |
| filed | Alan D. SobelDirector | Buy | +500 | $6.050 | $3 K | 9,787 | Form 4 |
| filed | Alan D. SobelDirector | Buy | +100 | $6.010 | $601 | 9,887 | Form 4 |
| filed | Vincent CapponiPresident and COO | Buy | +1,800 | $6.070 | $11 K | 40,114 | Form 4 |
| filed | Vincent CapponiPresident and COO | Buy | +273 | $5.900 | $2 K | 40,387 | Form 4 |
| filed | Phillip P. ChanChief Executive Officer, Director | Buy | +200,000 | $0.350 | $70 K | 1.94 M | Form 4 |
| filed | Peter J. MarianiChief Financial Officer | Buy | +100,000 | $0.440 | $44 K | 638,113 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Cytosorbents Corporation#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 1-for-20 reverse split ; 25-for-1 split
Trading halts
- 2026-10-16 18:22 UTC, code LUDP, resumed 18:27 UTC
- 2026-10-16 18:12 UTC, code LUDP, resumed 18:17 UTC
- 2026-10-16 18:06 UTC, code LUDP, resumed 18:11 UTC
- 2026-10-01 15:26 UTC, code LUDP, resumed 15:36 UTC
- 2026-09-04 23:50 UTC, code T3, resumed 13:00 UTC
Fails to deliver
- : 261 shares at $4.40
- : 61 shares at $5.24
- : 261 shares at $4.85
- : 601 shares at $5.35
- : 13,527 shares at $5.32
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Cytosorbents Corporation scorecard#
Passes 3 of the 16 checks that could be worked out: strongest in financial health (1 of 4), weakest in growth (1 of 6). Fiscal year 2025; market cap of Aug 1, 2026.
Valuationnot known
- –P/E below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
- –Price to book below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
- –Price to sales below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
- –Free cash flow yield above 5%The market cap dates from 2026-08-01, more than 60 days ago.
- –Earnings yield above the 10-year Treasury yieldThe market cap dates from 2026-08-01, more than 60 days ago.
- –The price assumes slower growth than the last three years'The market cap dates from 2026-08-01, more than 60 days ago.
Growth1 of 6
- ✓Revenue grew in the newest year4.1%Revenue up 4.1% in fiscal 2025.
- ✗Revenue up more than 5% a year over three years2.2%2.2% a year over the three years to fiscal 2025.
- ✗Faster growth over three years than its peers' median2.2%2.2% a year against Medical Devices's median of 10.8% (73 companies).
- ✗Earnings per share grew in the newest year-0.13 vs -0.38Diluted EPS -0.13 in fiscal 2025 against -0.38 the year before (report's currency).
- ✗Net income higher than five years earlier-$8 M-$8 M in fiscal 2025 against -$8 M in 2020.
- ✗Revenue rose in at least four of the last five years3 of 5Revenue rose in 3 of the five years to fiscal 2025.
Profitability1 of 5
- ✗Profitable in the newest year-$8 MNet income -$8 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- ✗Operating margin above its peers' median-39.8%-39.8% against Medical Devices's median of -8.2% (86 companies).
- ✗Return on equity above 15%-96.4%-96.4% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- ✓Operating margin wider than three years earlier-39.8%-39.8% in fiscal 2025 against -90.9% in 2022.
Financial health1 of 4
- ✓Short-term assets cover short-term liabilities2.1×Current ratio 2.12 at the end of fiscal 2025.
- ✗Debt below equity2.8×Debt to equity 2.83 at the end of fiscal 2025.
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- ✗Altman Z-score outside the distress zone-9.47Z-score -9.47 (distress zone) for fiscal 2025.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year14.3%Diluted shares up 14.3% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueThe market cap dates from 2026-08-01, more than 60 days ago.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Medical Devices, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from Cytosorbents Corporation's statements, beside the median of Medical Devices.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Operating margin | -39.8% | -8.2% | |
| Net margin | -22.1% | -10.4% | |
| Return on equity | -96.4% | -16.8% | |
| Revenue growth, 3 years a year | 2.2% | 10.8% | |
| Revenue growth | 4.1% | 10.4% | |
| Debt to equity | 2.83× | 0.64× |
3of 9on the Piotroski tests of financial strength
- Net loss of $8 million, the 16th loss-making year in a row.
- Free cash flow was negative: -$13 million.
- The share count rose 14.3% in the year.
Cytosorbents Corporation: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 37+4.1%100% | 36r36+14.5%100% | 31r36−10.4%100% | 35−19.6%100% | 43+5.3%100% | 41+64.4%100% | 25+10.9%100% | 23+48.5%100% | 15+59.0%100% | 9.5—100% | |
| Cost of revenue | 11−1.3%28.5% | 11r10+17.3%30.1% | 9.1r14−34.6%29.4% | 14+26.3%40.2% | 11−0.0%25.6% | 11+50.1%27.0% | 7.4−1.7%29.5% | 7.5+35.7%33.3% | 5.5+39.6%36.4% | 4.0—41.5% | |
| Gross profit | 26+6.4%71.5% | 25r25+13.4%69.9% | 22r22+5.9%70.6% | 21−35.4%59.8% | 32+7.2%74.4% | 30+70.3%73.0% | 18+17.1%70.5% | 15+55.9%66.7% | 9.6+72.8%63.6% | 5.6—58.5% | |
| Research and development | — | — | 16+4.0%50.6% | 15−7.7%43.6% | 16+85.9%37.9% | 8.8−27.1%21.5% | 12+56.6%48.5% | 7.7+140%34.3% | 3.2r4.0−20.9%21.3% | 4.1r4.8—42.7% | |
| Selling, general and administrative | 36+5.7%96.2% | 34r35−11.9%94.8% | 38r34+11.7%123% | 34−4.1%98.8% | 36+25.6%82.8% | 28+29.3%69.4% | 22+5.4%88.2% | 21+40.0%92.8% | 15r14+26.3%98.4% | 12r11—124% | |
| Operating expenses | 41−0.2%111% | 41r42−23.3%116% | 54r54+3.2%173% | 52−4.8%151% | 55+36.1%127% | 40+10.3%98.3% | 37+19.5%147% | 31+57.1%136% | 19+14.1%129% | 17—179% | |
| Operating income | −15—−39.8% | −16r−17—−46.2% | −32r−31—−103% | −32—−90.9% | −23—−52.7% | −10—−25.3% | −19—−76.0% | −16—−69.3% | −9.8—−65.0% | −11—−121% | |
| Other non-operating income (expense) | 6.2—16.6% | −6.0r−5.6−416%−16.7% | 1.9r1.9—6.1% | −2.4—−6.9% | −2.5−281%−5.9% | 1.4—3.4% | −1.4—−5.5% | −2.2−419%−10.0% | 0.7—4.7% | −0.6r−0.8—−6.2% | |
| Income before tax | −8.6—−23.2% | −22r−22—−63.0% | −30r−29—−96.7% | −34—−97.7% | −25—−58.6% | −9.0—−21.9% | −20—−81.6% | −18—−79.2% | −9.1—−60.3% | −12r−12—−127% | |
| Income tax | −0.4—−1.1% | −1.7r−1.7—−4.8% | −0.8—−2.6% | −1.1—−3.1% | −0.7—−1.7% | −1.1—−2.7% | −1.1—−4.4% | −0.6—−2.8% | −0.7—−4.5% | −0.3—−3.3% | |
| Net income including minority interests | −8.2—−22.1% | −21—−58.2% | — | — | — | — | — | — | — | — | |
| Net income attributable to shareholders | −8.2—−22.1% | −21r−21—−58.2% | −29r−29—−94.1% | −33—−94.6% | −25—−56.9% | −7.8—−19.1% | −19—−77.2% | −17—−76.5% | −8.5—−55.8% | −12r−12—−123% | |
| Earnings per share, basic | -0.13—— | -0.38—— | -0.65r-0.64—— | -0.75—— | -0.57—— | -0.20—— | -0.60—— | -0.56—— | -0.32—— | -0.46r-0.47—— | |
| Earnings per share, diluted | -0.13—— | -0.38—— | -0.65r-0.64—— | -0.75—— | -0.57—— | -0.20—— | -0.60—— | -0.56—— | -0.32—— | -0.46r-0.47—— | |
| Shares, weighted average (basic) | 62+14.3%— | 54+21.9%— | 45+2.5%— | 44+0.5%— | 43+11.7%— | 39+20.3%— | 32—— | — | — | — | |
| Shares, weighted average (diluted) | 62+14.3%— | 54+21.9%— | 45+2.5%— | 44+0.5%— | 43+11.7%— | 39+20.3%— | 32+5.0%— | 31+11.2%— | 28+8.6%— | 25—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 6.2+90.5%14.1% | 3.3r3.3−76.8%6.9% | 14−36.2%26.7% | 22−57.5%35.0% | 52−27.0%58.2% | 71+484%79.4% | 12−45.3%44.7% | 22+29.1%65.4% | 17+230%71.9% | 5.2—54.1% | |
| Short-term investments | — | — | — | — | — | — | — | — | — | 0—0.0% | |
| Receivables | 7.6+3.1%17.1% | 7.3r7.3+20.9%15.5% | 6.1+6.9%11.4% | 5.7+25.2%9.0% | 4.5−12.3%5.1% | 5.2+15.5%5.7% | 4.5+13.3%16.3% | 3.9+78.8%11.5% | 2.2+53.9%9.2% | 1.4—14.8% | |
| Inventory | 5.3+93.2%12.0% | 2.7r2.7−19.0%5.8% | 3.4r3.7−2.5%6.4% | 3.5−27.4%5.5% | 4.8+78.3%5.3% | 2.7+26.5%3.0% | 2.1+154%7.7% | 0.8+4.7%2.4% | 0.8−4.6%3.3% | 0.8—8.6% | |
| Other current assets | 1.6−52.5%3.5% | 3.3r3.3+78.3%6.9% | 1.8−26.3%3.5% | 2.5−13.3%3.9% | 2.9−10.2%3.2% | 3.2+53.2%3.6% | 2.1+86.6%7.6% | 1.1+169%3.3% | 0.4+31.7%1.7% | 0.3—3.3% | |
| Current assets | 21−4.5%46.7% | 22r22−14.9%45.6% | 25r26−24.8%48.0% | 34−47.5%53.4% | 64−22.0%71.8% | 82+294%91.7% | 21−26.0%76.3% | 28+36.3%82.7% | 21+165%86.0% | 7.8—80.8% | |
| Property, plant and equipment | 7.8−13.1%17.7% | 9.0r9.0−10.5%19.0% | 10−6.4%19.0% | 11+109%17.0% | 5.2+143%5.8% | 2.1+10.1%2.4% | 1.9+11.3%7.0% | 1.7+23.3%5.1% | 1.4+146%5.8% | 0.6—5.9% | |
| Right-of-use (leased) assets | 11−5.1%24.7% | 12r12−4.5%24.3% | 12−4.3%22.8% | 13−6.1%19.9% | 13+1204%15.0% | 1.0−3.9%1.1% | 1.1−26.1%3.9% | 1.4—4.2% | — | — | |
| Other intangible assets | 3.2−13.3%7.3% | 3.7r3.7−4.7%7.9% | 3.9−11.0%7.4% | 4.4−6.6%6.9% | 4.7+11.4%5.3% | 4.2+25.6%4.7% | 3.4+28.0%12.3% | 2.6+42.8%7.7% | 1.8—7.6% | — | |
| Non-current assets | — | — | — | — | — | — | — | — | — | 1.9—19.2% | |
| Total assets | 44−6.7%100% | 47r47−10.5%100% | 53r53−16.3%100% | 63−29.4%100% | 90−0.5%100% | 90+228%100% | 27−19.9%100% | 34r33+41.9%100% | 24+149%100% | 9.7—100% | |
| Accounts payable | 2.9−14.1%6.5% | 3.3r3.3−12.2%7.1% | 3.8+130%7.2% | 1.7−41.0%2.6% | 2.8+52.9%3.1% | 1.8−10.0%2.0% | 2.0+37.2%7.4% | 1.5+19.4%4.3% | 1.2−6.4%5.2% | 1.3—13.7% | |
| Debt due within a year | — | — | 2.5—4.7% | — | — | 0−100%0.0% | 1.7+150%6.1% | 0.7−83.3%1.9% | 4.0+380%16.6% | 0.8—8.6% | |
| Current liabilities | 9.7−1.2%22.0% | 9.8r9.8−30.0%20.7% | 14r15+44.5%26.5% | 9.7−29.0%15.4% | 14+34.8%15.3% | 10+2.2%11.3% | 9.9+43.7%36.3% | 6.9r6.5−11.9%20.2% | 7.8+83.5%32.6% | 4.3r6.1—44.1% | |
| Long-term debt | 17+19.1%37.7% | 14r14+450%29.5% | 2.5−49.1%4.8% | 5.0—7.9% | — | 0−100%0.0% | 13+44.3%48.9% | 9.3+54.8%27.1% | 6.0+46.9%24.9% | 4.1—42.1% | |
| Lease liabilities (non-current) | 12−4.3%26.9% | 12r12−3.5%26.3% | 13−1.9%24.4% | 13−0.8%20.8% | 13+2178%14.8% | 0.6−9.5%0.6% | 0.6−40.0%2.3% | 1.1—3.1% | — | — | |
| Total liabilities | 38+5.6%86.6% | 36r36+23.0%76.6% | 29r30+5.8%55.7% | 28+3.4%44.1% | 27+151%30.1% | 11−55.2%11.9% | 24+38.8%87.5% | 17r16+24.7%50.5% | 14+65.6%57.4% | 8.4r10—86.2% | |
| Retained earnings | −312—−707% | −304r−304—−642% | −283r−283—−535% | −254—−402% | −221—−247% | −197—−219% | −189—−689% | −170—−496% | −152—−632% | −144r−144—−1480% | |
| Shareholders' equity | 5.9−46.9%13.4% | 11r11−52.7%23.4% | 23r23−33.6%44.3% | 35−43.5%55.9% | 63−21.0%69.9% | 79+2218%88.1% | 3.4−79.8%12.5% | 17+65.0%49.5% | 10+667%42.6% | 1.3r−0.5—13.8% | |
| Total liabilities and equity | 44−6.7%100% | 47r47−10.5%100% | 53r53−16.3%100% | 63−29.4%100% | 90−0.5%100% | 90+228%100% | 27−19.9%100% | 34r33+41.9%100% | 24+149%100% | 9.7—100% | |
| Shares outstanding | 63+14.5%— | 55+1.1%— | 54+24.3%— | 44r430.0%— | 44r43+1.0%— | 43+32.5%— | 33+2.6%— | 32+9.7%— | 29+13.7%— | 25—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | 1.2−7.6%3.3% | 1.3r1.6−8.5%3.8% | 1.5r1.5+65.3%4.7% | 0.9+20.6%2.5% | 0.7+10.7%1.7% | 0.7+13.6%1.6% | 0.6+48.9%2.3% | 0.4+78.9%1.7% | 0.2+35.1%1.4% | 0.2—1.7% | |
| Share-based compensation | 2.8−26.5%7.5% | 3.8r3.8−9.5%10.6% | 4.2r3.3+21.4%13.4% | 3.4−14.9%9.9% | 4.0+14.4%9.3% | 3.5+111%8.6% | 1.7−62.5%6.7% | 4.4+33.9%19.7% | 3.3+20.2%21.9% | 2.8—28.9% | |
| Cash from operating activities | −12—−33.4% | −14r−14—−40.5% | −22—−69.7% | −28—−81.4% | −14—−32.4% | −5.6—−13.7% | −17—−67.2% | −11—−48.2% | −6.5—−42.6% | −6.7—−70.6% | |
| Capital expenditure | −0.2—−0.4% | −0.3r−0.3—−0.8% | −0.5—−1.7% | −6.1—−17.5% | −3.6—−8.4% | −0.7—−1.7% | −0.7—−2.8% | −0.7—−3.0% | −1.0—−6.5% | −0.1—−1.5% | |
| Intangible assets bought | −0.3—−0.9% | −0.4r−0.4—−1.1% | −0.4—−1.3% | −0.4—−1.1% | −0.6—−1.5% | −1.0—−2.4% | −0.8—−3.3% | −0.8—−3.8% | −0.7—−4.5% | −0.5—−4.8% | |
| Cash from investing activities | −0.4—−1.1% | −0.7r−0.7—−1.9% | −0.9—−3.0% | −6.5—−18.6% | −4.3—−9.9% | −1.7—−4.1% | −1.5—−6.1% | −1.5—−6.8% | −1.7−205%−11.1% | 1.6—16.8% | |
| Debt issued | 2.5−83.5%6.7% | 15—42.1% | — | 5.0—14.4% | — | 1.4−71.8%3.4% | 5.0+650%20.0% | 0.7−86.7%3.0% | 5.00.0%33.0% | 5.0—52.5% | |
| Debt repaid | — | −5.0—−14.0% | — | — | — | −16—−40.0% | 0—0.0% | −0.7—−3.0% | 0—0.0% | 0—0.0% | |
| Shares issued | — | — | — | — | 270.0%63.0% | 27+92.5%66.3% | 14+37.2%56.6% | 100.0%45.8% | 10—68.0% | — | |
| Cash from financing activities | 9.3−0.2%25.1% | 9.3r9.3−35.5%26.2% | 14+192%46.6% | 5.0+593%14.3% | 0.7−98.9%1.7% | 66+711%162% | 8.2−53.2%32.8% | 17−13.2%77.6% | 20+297%133% | 5.1—53.2% | |
| Exchange-rate effect on cash | — | — | — | — | −0.0−119%−0.1% | 0.1—0.3% | −0.0—−0.1% | −0.1−164%−0.3% | 0.1—0.6% | −0.0—−0.0% | |
| Change in cash | −2.0—−5.4% | −5.9r−5.9—−16.4% | −8.2—−26.4% | −30—−86.5% | −18−130%−40.8% | 59—144% | −10−301%−40.6% | 5.0−58.2%22.4% | 12—79.7% | −0.1—−0.8% | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Jun 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 | Q3 FY2023to Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 37+3.1%100% | 9.6+0.2%100% | 8.9+1.6%100% | 9.2*+0.9%100% | 9.5+10.1%100% | 9.6+8.8%100% | 8.7r8.7−2.9%100% | 9.2r6.5*+5.6%100% | 8.6r9.4−2.2%100% | 8.8r9.9—100% | 9.0r9.8—100% | 8.7—100% | 8.8—100% | |
| Cost of revenue | 11−8.7%28.4% | 2.6−7.8%26.8% | 2.7+8.5%30.8% | 2.4*−16.1%26.3% | 2.8−16.0%29.7% | 2.8+19.8%29.1% | 2.5r2.5+19.1%28.9% | 2.9r2.7*—31.6% | 3.4r4.1+4.8%39.0% | 2.3r3.4—26.5% | 2.1r3.2—23.5% | — | 3.2—36.4% | |
| Gross profit | 27+8.6%71.6% | 7.0+3.4%73.2% | 6.1−1.2%69.2% | 6.8*+8.8%73.7% | 6.7+26.8%70.3% | 6.8+4.8%70.9% | 6.2r6.2−9.7%71.1% | 6.3r6.8*+17.8%68.4% | 5.3r5.3−6.3%61.0% | 6.5r6.5—73.5% | 6.9r6.6—76.5% | 5.3—61.3% | 5.6—63.6% | |
| Research and development | — | 1.5+15.1%15.1% | 1.0−38.4%11.6% | — | — | 1.3−17.0%13.1% | 1.7−26.0%19.1% | — | 1.9−50.6%21.5% | 1.5—17.2% | 2.2—25.0% | 4.1*—47.3% | 3.7—42.6% | |
| Selling, general and administrative | 34+2.0%91.8% | 8.0−13.1%82.7% | 8.1−3.4%91.9% | 9.4*+23.6%102% | 8.6+4.2%90.8% | 9.2+7.2%95.3% | 8.4r8.4−9.2%96.6% | 7.6r12*−45.3%83.4% | 8.3r7.0+1.9%95.9% | 8.6r7.6—96.7% | 9.3r8.6—103% | 14r9.2*—161% | 8.1—92.0% | |
| Operating expenses | 40−1.7%106% | 9.7−7.1%101% | 9.2−9.1%103% | 11*+15.9%121% | 9.5−5.5%100% | 10+3.5%108% | 10r10−12.4%116% | 9.7r11*−35.5%105% | 10r9.7−22.2%117% | 10r9.9—114% | 12r11—128% | 15r15*—173% | 13—147% | |
| Operating income | −13—−34.7% | −2.6—−27.4% | −3.0—−34.3% | −4.4*—−47.5% | −2.9—−30.2% | −3.6—−37.6% | −3.9r−3.9—−44.6% | −3.4r−4.0*—−37.1% | −4.8r−4.4—−56.1% | −3.6r−3.4—−40.4% | −4.7r−4.9—−51.8% | −9.4—−109% | −7.4—−83.4% | |
| Other non-operating income (expense) | −5.7−236%−15.3% | −1.8−132%−18.5% | −2.1−187%−23.5% | −1.1*—−12.0% | −0.7−134%−7.5% | 5.6—57.8% | 2.4r2.4—27.6% | −5.9r−5.5*−318%−64.1% | 2.1r2.1—23.9% | −0.7r−0.7—−8.2% | −1.4—−15.9% | 2.7r2.7*—31.1% | −1.8—−20.9% | |
| Income before tax | — | — | — | −5.5*—−59.5% | −3.6—−37.6% | — | −1.5—−16.9% | −9.3r−9.6*—−101% | −2.8r−2.3—−32.1% | −4.1—−46.9% | −6.1r−6.4—−67.7% | −7.4r−6.6*—−85.2% | −9.2—−104% | |
| Income tax | −0.4—−1.1% | 0—0.0% | 0—0.0% | 0*—0.0% | −0.4—−4.2% | 0—0.0% | 0—0.0% | −1.7r−1.7*—−18.5% | 0—0.0% | 0*—0.0% | 0—0.0% | −0.8*—−9.4% | 0—0.0% | |
| Net income including minority interests | −18—−48.9% | −4.4*−327%−45.9% | −5.1—−57.9% | −5.5*—−59.5% | −3.2*—−33.4% | 1.9*—20.3% | −1.5—−16.9% | −7.6*—−82.7% | −2.8*—−32.1% | — | — | — | — | |
| Net income attributable to shareholders | −18—−48.9% | −4.4−327%−45.9% | −5.1—−57.9% | −5.5*—−59.5% | −3.2—−33.4% | 1.9—20.2% | −1.5r−1.5—−16.9% | −7.6r−7.9*—−82.7% | −2.8r−2.3—−32.1% | −4.3r−4.1—−48.6% | −6.1r−6.4—−67.7% | −6.6r−5.8*—−75.8% | −9.2—−104% | |
| Earnings per share, basic | — | -0.07−333%— | -0.08—— | — | -0.05—— | 0.03—— | -0.02—— | — | -0.05r-0.04—— | -0.08—— | -0.11r-0.12—— | -0.12—— | -0.21—— | |
| Earnings per share, diluted | — | -0.07−333%— | -0.08—— | — | -0.05—— | 0.03—— | -0.02—— | — | -0.05r-0.04—— | -0.08—— | -0.11r-0.12—— | -0.12—— | -0.21—— | |
| Shares, weighted average (basic) | 63+0.3%— | 63+0.3%— | 63+3.3%— | — | 63+15.2%— | 63+15.3%— | 61+11.6%— | — | 54+22.7%— | 54—— | 54r54—— | — | 44—— | |
| Shares, weighted average (diluted) | 63−6.5%— | 63−6.5%— | 63+3.3%— | — | 63+15.2%— | 67+23.7%— | 61+11.6%— | — | 54+22.7%— | 54—— | 54r54—— | — | 44—— | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 4.4—11.6% | 4.4−56.8%11.6% | 4.8−58.5%11.9% | 6.2+90.5%14.1% | 7.5+32.6%16.5% | 10+20.6%21.3% | 12+34.6%22.8% | 3.3r3.3−76.8%6.9% | 5.7−32.0%11.9% | 8.5—15.8% | 8.6—18.3% | 14—26.7% | 8.4—17.6% | |
| Receivables | 6.8—17.9% | 6.8−12.4%17.9% | 7.2−6.8%17.6% | 7.6+3.1%17.1% | 7.4+12.0%16.2% | 7.7−1.0%16.1% | 7.7+13.4%15.1% | 7.3r7.3+20.9%15.5% | 6.6+7.3%13.9% | 7.8—14.6% | 6.8—14.4% | 6.1—11.4% | 6.2—13.0% | |
| Inventory | 3.7—9.7% | 3.7−0.6%9.7% | 4.5+48.5%11.0% | 5.3+93.2%12.0% | 4.0+23.2%8.7% | 3.7−14.1%7.7% | 3.0−19.3%5.9% | 2.7r2.7−19.0%5.8% | 3.2+9.1%6.8% | 4.3—8.1% | 3.7—7.9% | 3.4r3.7—6.4% | 3.0—6.3% | |
| Other current assets | 0.9—2.2% | 0.9−35.9%2.2% | 1.3−58.2%3.2% | 1.6−52.5%3.5% | 2.3+128%5.1% | 1.3−2.0%2.8% | 3.1+256%6.2% | 3.3r3.3+78.3%6.9% | 1.0−40.9%2.2% | 1.4—2.5% | 0.9—1.9% | 1.8—3.5% | 1.7—3.7% | |
| Current assets | 16—41.5% | 16−31.5%41.5% | 18−30.1%43.8% | 21−4.5%46.7% | 21+28.4%46.6% | 23+4.7%47.9% | 25+27.1%50.0% | 22r22−14.9%45.6% | 17−13.8%34.7% | 22—41.1% | 20—42.5% | 25r26—48.0% | 19—40.5% | |
| Property, plant and equipment | 7.2—18.9% | 7.2−15.3%18.9% | 7.5−13.9%18.5% | 7.8−13.1%17.7% | 8.2−11.6%17.9% | 8.5−10.2%17.6% | 8.7−10.5%17.2% | 9.0r9.0−10.5%19.0% | 9.3−9.8%19.4% | 9.4—17.6% | 9.7—20.7% | 10—19.0% | 10—21.6% | |
| Right-of-use (leased) assets | 11—28.0% | 11−5.4%28.0% | 11−5.3%26.5% | 11−5.1%24.7% | 11−4.9%24.2% | 11−4.8%23.4% | 11−4.7%22.4% | 12r12−4.5%24.3% | 12−4.5%24.4% | 12—22.1% | 12—25.3% | 12—22.8% | 12—25.6% | |
| Other intangible assets | 2.9—7.5% | 2.9−23.4%7.5% | 3.0−20.3%7.3% | 3.2−13.3%7.3% | 3.6—7.9% | 3.7—7.8% | 3.7—7.3% | 3.7r3.7−4.7%7.9% | — | — | — | 3.9—7.4% | — | |
| Total assets | 38—100% | 38−20.9%100% | 41−20.1%100% | 44−6.7%100% | 46−4.3%100% | 48−10.2%100% | 51+7.9%100% | 47r47−10.5%100% | 48+0.5%100% | 53—100% | 47—100% | 53r53—100% | 48—100% | |
| Accounts payable | 2.0—5.3% | 2.0−41.0%5.3% | 3.1−5.8%7.7% | 2.9−14.1%6.5% | 3.0+29.8%6.6% | 3.4+11.4%7.1% | 3.3+38.6%6.5% | 3.3r3.3−12.2%7.1% | 2.3−32.1%4.9% | 3.0—5.7% | 2.4—5.1% | 3.8—7.2% | 3.4—7.2% | |
| Debt due within a year | 14—37.3% | 14—37.3% | 6.6—16.4% | — | — | — | — | — | — | — | 2.5—5.3% | 2.5—4.7% | 0.8—1.8% | |
| Current liabilities | 24—63.3% | 24+144%63.3% | 16+67.4%40.2% | 9.7−1.2%22.0% | 10+22.1%22.1% | 9.8+2.1%20.5% | 9.7−23.5%19.2% | 9.8r9.8−30.0%20.7% | 8.3r8.4−29.0%17.3% | 9.6r10—18.1% | 13r13—27.0% | 14r15—26.5% | 12r12—24.5% | |
| Long-term debt | 3.1—8.1% | 3.1−78.5%8.1% | 10−27.3%25.4% | 17+19.1%37.7% | 15+5.5%31.8% | 14+5.1%30.0% | 14+636%27.9% | 14r14+450%29.5% | 14+229%28.9% | 14—25.6% | 1.9—4.1% | 2.5—4.8% | 4.2—8.8% | |
| Lease liabilities (non-current) | 12—30.5% | 12−4.8%30.5% | 12−4.6%29.0% | 12−4.3%26.9% | 12−4.1%26.3% | 12−3.9%25.4% | 12−3.7%24.3% | 12r12−3.5%26.3% | 13−2.5%26.3% | 13—23.7% | 13—27.2% | 13—24.4% | 13—27.1% | |
| Total liabilities | 39—102% | 39+6.3%102% | 38+5.9%94.6% | 38+5.6%86.6% | 37+6.0%80.3% | 36+1.1%75.9% | 36+32.1%71.4% | 36r36+23.0%76.6% | 35r35+20.5%72.5% | 36r37—67.4% | 27r28—58.3% | 29r30—55.7% | 29r29—60.5% | |
| Retained earnings | −322—−848% | −322—−848% | −317—−782% | −312—−707% | −307—−670% | −304—−633% | −305—−602% | −304r−304—−642% | −296r−295—−620% | −294r−293—−550% | −289r−289—−615% | −283r−283—−535% | −277r−277—−583% | |
| Shareholders' equity | −0.8—−2.0% | −0.8−106%−2.0% | 2.2−84.9%5.4% | 5.9−46.9%13.4% | 9.0−32.6%19.7% | 12−33.5%24.1% | 15r15−25.9%28.6% | 11r11−52.7%23.4% | 13r13−28.9%28.0% | 17r17—32.6% | 20r19—41.7% | 23r23—44.3% | 19r19—39.5% | |
| Total liabilities and equity | 38—100% | 38−20.9%100% | 41−20.1%100% | 44−6.7%100% | 46−4.3%100% | 48−10.2%100% | 51+7.9%100% | 47r47−10.5%100% | 48r48+0.5%100.0% | 53r53—100.0% | 47—100% | 53r53—100% | 48—100% | |
| Shares outstanding | 63—— | 63+0.4%— | 63+0.3%— | 63+14.5%— | 63+15.2%— | 63+15.3%— | 63+15.2%— | 55+1.1%— | 55+24.3%— | 54—— | 54—— | 54—— | 44—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | — | — | — | 0.1*−37.0%1.1% | 0.5r0.4*+27.4%5.1% | 0.3r0.4*−30.0%2.9% | 0.4−7.2%4.2% | 0.2r0.4*−60.6%1.7% | 0.4r0.4*−5.9%4.4% | 0.4r0.4*—4.5% | 0.4—4.4% | 0.4r0.4*—4.5% | 0.4*—4.6% | |
| Share-based compensation | 2.3−28.6%6.1% | 0.4−35.6%3.8% | 0.5−33.5%6.1% | 0.9*−3.7%9.6% | 0.5−45.2%5.1% | 0.6−42.3%5.9% | 0.8r0.8−14.7%9.4% | 0.9r1.4*−44.9%10.1% | 0.9r0.8−18.0%10.3% | 1.0r0.8—11.2% | 1.0r0.7—10.7% | 1.7r0.8*—19.3% | 1.1—12.3% | |
| Cash from operating activities | −9.1—−24.6% | −0.6*—−6.1% | −1.2—−13.1% | −4.8*—−52.3% | −2.6*—−27.2% | −1.5r−1.5*—−15.7% | −3.5r−3.5—−39.7% | −2.3r−2.3*—−25.6% | −2.5r−2.5*—−28.6% | −4.8r−4.8*—−54.2% | −4.8—−53.7% | −6.4*—−73.9% | −5.2*—−59.1% | |
| Capital expenditure | −0.2—−0.4% | −0.0*—−0.1% | −0.0—−0.1% | −0.1*—−1.2% | −0.0*—−0.2% | −0.0r−0.0*—−0.4% | −0.0r−0.0—−0.0% | −0.1r−0.1*—−0.8% | −0.2*—−1.8% | −0.0*—−0.2% | −0.0—−0.5% | −0.1*—−1.1% | −0.1*—−1.6% | |
| Intangible assets bought | — | −0.0*—−0.4% | −0.1—−0.7% | −0.3*—−2.8% | — | −0.1r−0.1*—−1.0% | −0.0r−0.0—−0.5% | −0.1r−0.1*—−0.6% | −0.1r−0.1*—−1.7% | −0.1r−0.1*—−1.1% | −0.1—−0.9% | −0.0*—−0.5% | −0.1*—−1.3% | |
| Cash from investing activities | −0.3—−0.7% | 0.0*—0.1% | −0.0—−0.5% | −0.3*—−3.2% | 0.1*—0.6% | −0.1r−0.1*—−1.4% | −0.0r−0.0—−0.5% | −0.1r−0.1*—−1.4% | −0.3r−0.3*—−3.5% | −0.1r−0.1*—−1.3% | −0.1—−1.4% | −0.1*—−1.6% | −0.3*—−2.9% | |
| Debt issued | — | — | — | — | — | — | — | 0*—0.0% | 0*—0.0% | — | — | — | — | |
| Debt repaid | — | — | — | — | — | — | — | 0*—0.0% | 0*—0.0% | −4.4*—−49.5% | −0.6—−7.0% | — | — | |
| Shares issued | — | — | — | — | — | — | — | — | — | — | 0.1—0.6% | — | — | |
| Cash from financing activities | — | — | — | 2.5*+1384%26.8% | 0*—0.0% | 0r−0.0*−100%0.0% | 6.8r6.8—78.3% | 0.2r0.2*−98.6%1.8% | −0.1r−0.1*−115%−1.1% | 9.8r9.8*—111% | −0.6—−6.4% | 12*—141% | 0.6*—7.4% | |
| Change in cash | −5.8—−15.6% | −0.4*—−4.2% | −1.4−143%−16.2% | −1.3*—−13.9% | −2.7*—−28.1% | −1.4r−1.4*−129%−14.4% | 3.3r3.3—38.3% | −2.4r−2.4*−143%−26.3% | −2.8r−2.8*—−32.2% | 4.9r4.9*—54.9% | −5.5—−61.4% | 5.6*—64.2% | −4.8*—−54.4% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Jun 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What Cytosorbents Corporation sells: revenue by product line, fiscal 2025#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.
Products and services
- Total product sales(total)$37 M100%+4.1%
Business segments
- Single reportable segment$37 M100%+4.1%
Source: SEC annual report (XBRL data) · as of Dec 31, 2025
Where Cytosorbents Corporation operates: 8 countries#
Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 8 subsidiaries on file.
| Country | Presence | Revenue there |
|---|---|---|
| 🇺🇸 USA | Headquarters2 offices1 subsidiary | — |
| 🇨🇦 Canada | 1 subsidiary | — |
| 🇫🇷 France | 1 subsidiary | — |
| 🇩🇪 Germany | 1 subsidiary | — |
| 🇮🇳 India | 1 subsidiary | — |
| 🇵🇱 Poland | 1 subsidiary | — |
| 🇨🇭 Switzerland | 1 subsidiary | — |
| 🇬🇧 UK | 1 subsidiary | — |
Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided
Executive pay at Cytosorbents Corporation#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Dr. Phillip P. Chan | $808 K | $723 K | $679 K | $12 |
| 2024Phillip P. Chan | $900 K | $953 K | $896 K | $17 |
| 2023Phillip P. Chan | $1.3 M | $730 K | $995 K | $20 |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at Cytosorbents Corporation#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
Delisting notice 3 · Financial statements withdrawn 1 · Acquisition or sale completed 1 · Bylaws or fiscal year changed 1 · Shareholder vote 2 · Results announced 9
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Bylaws or fiscal year changed | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Delisting notice | 8-K | |
| Results announced | 8-K | |
| Delisting notice | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Delisting notice | 8-K | |
| Acquisition or sale completed | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Financial statements withdrawn | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026
Acquisitions and funding#
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Jun 2013 | $1 M | Private placement after listing | Under $2 million | 24 | debt, options | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
How Cytosorbents Corporation compares in Medical Devices
- Market cap$25 M · higher than 16% of 142
- Revenue$37 M · higher than 25% of 155
- Net margin-49.0% · higher than 23% of 144
- Revenue growth4.1% · higher than 29% of 104
- Price / sales0.7× · lower than 93% of 96
- Price / book4.2× · lower than 35% of 99
- FCF yield-50.2% · higher than 17% of 76
Peer comparison · Medical Devices
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Cytosorbents Corporation🇺🇸 | $25 M | — | -49.0% | +4.1% |
| Abbott Laboratories🇺🇸 | $181.1 B | 38.5× | 9.8% | +5.7% |
| Medtronic plc🇺🇸 | $121.2 B | 23.2× | 13.9% | +8.4% |
| Stryker Corporation🇺🇸 | $116.5 B | 32.2× | 13.8% | +11.2% |
| Boston Scientific Corporation🇺🇸 | $66.2 B | 18.9× | 16.6% | +19.9% |
| Edwards Lifesciences Corporation🇺🇸 | $52.8 B | 51.7× | 15.3% | +11.6% |
| Shenzhen Mindray Bio-Medical Electronics Co., Ltd.🇨🇳 | $27.8 B | 23.6× | 24.4% | — |
| STERIS plc🇮🇪 | $20.4 B | 24.6× | 13.4% | +8.7% |
| Zimmer Biomet Holdings, Inc.🇺🇸 | $18.2 B | 23.8× | 8.9% | +7.2% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- InspireMD, Inc.$24 M
- AmCad BioMed Corporation$23 M
- Wiltrom Co., Ltd.$27 M
- Radiant Innovation Inc.$23 M
- Rossmax International Ltd.$27 M
- Nureca Limited$31 M
Sources and freshness
- Market cap:
- Aug 1, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, Wikipedia; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Cytosorbents Corporation? Verify and update this profile — free
Show Cytosorbents Corporation's ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.